Hypoxia But Not Inflammation Augments Glucose Uptake in Human Macrophages Implications for Imaging Atherosclerosis With 18Fluorine-Labeled 2-Deoxy-D-Glucose Positron Emission Tomography by Folco, Eduardo J. et al.
Journal of the American College of Cardiology Vol. 58, No. 6, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Cardiac Imaging
Hypoxia But Not Inflammation
Augments Glucose Uptake in Human Macrophages
Implications for Imaging Atherosclerosis With
18Fluorine-Labeled 2-Deoxy-D-Glucose Positron Emission Tomography
Eduardo J. Folco, PHD,* Yuri Sheikine, MD,†‡ Viviane Z. Rocha, MD,* Thomas Christen, MD,*
Eugenia Shvartz, BS,* Galina K. Sukhova, PHD,* Marcelo F. Di Carli, MD,*†‡ Peter Libby, MD*
Boston, Massachusetts
Objectives This study investigated the regulation of glucose uptake in cells that participate in atherogenesis by stimuli rele-
vant to this process, to gain mechanistic insight into the origin of the 18fluorine-labeled 2-deoxy-D-glucose (FdG)
uptake signals observed clinically.
Background Patient studies suggest that positron emission tomography (PET) using FdG can detect “active” atherosclerotic
plaques, yet the mechanism giving rise to FdG signals remains unknown.
Methods We exposed cells to conditions thought to operate in atheroma and determined rates of glucose uptake.
Results Hypoxia, but not pro-inflammatory cytokines, potently stimulated glucose uptake in human macrophages and
foam cells. Statins attenuated this process in vitro, suggesting that these agents have a direct effect on human
macrophages. Immunohistochemical study of human plaques revealed abundant expression of proteins regulat-
ing glucose utilization, predominantly in macrophage-rich regions of the plaques—regions previously proved
hypoxic. Smooth-muscle cells and endothelial cells markedly increased rates of glucose uptake when exposed to
pro-inflammatory cytokines.
Conclusions Glucose uptake and, probably, FdG uptake signals in atheroma may reflect hypoxia-stimulated macrophages
rather than mere inflammatory burden. Cytokine-activated smooth-muscle cells also may contribute to
the FdG signal. (J Am Coll Cardiol 2011;58:603–14) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.044Interest abounds in functional imaging methods that might
report aspects of atherosclerotic plaque biology related to
clinical complications. Positron emission tomography
(PET) stands out in this respect, as it noninvasively assesses
pathophysiologic processes taking place in the imaged
tissue, and uses an already approved imaging agent,
18fluorine-labeled 2-deoxy-D-glucose (FdG), currently in
widespread use in cancer imaging (1).
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2011, accepted March 22, 2011.Some animal studies have demonstrated that PET can
detect FdG uptake in aortic atherosclerotic lesions and in
balloon-injured arteries (2–8). Several clinical studies have
shown FdG accumulation in human atherosclerotic arteries.
Many of these studies were retrospective, reporting inciden-
tal findings of increased FdG uptake in projections of large
vessels in cancer patients (9–13), whereas other studies were
designed specifically to evaluate the intensity of FdG signals
colocalized with major arteries (mostly carotid arteries) (14).
See page 615
Seeking to determine the source of the FdG signal in plaques,
several studies correlated the uptake of FdG or tritiated 2-deoxy-
D-glucose (3H-2dG) with macrophage content in human end-
arterectomy specimens and in experimentally produced lesions in
rabbits (2–6,14,15). Further in vitro studies showed that certain
pro-atherogenic stimuli (e.g., lipopolysaccharide and interferon-
[IFN-]) increased 3H-2dG and FdG uptake by cultured mono-
ytes and macrophages (16–18). Taken together, these findings
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take reflects inflammatory activation
of plaque macrophages and poten-
tially the propensity of plaques to
rupture. This notion recently has
gained wide currency in the field of
atherosclerosis research. Several
clinical investigations now under
way use FdG uptake as an indica-
tor of inflammation in human ath-
erosclerotic plaques. In this re-
gard, 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors
(statins), known to have anti-
inflammatory effects, have decreased
FdG uptake in serial studies of pa-
tients with atherosclerosis (19).
These observations have reinforced
the conjecture that FdG uptake
measures inflammation.
Yet, association between mac-
rophage content in plaques and
FdG uptake does not prove a
causal relationship between in-
flammation and FdG uptake. In-
deed, not all studies have sub-
stantiated this association. For
example, Matter et al. (20) dem-
onstrated poor correlation be-
tween 14C-2dG imaging signals
and the amount of macrophage
and lipid staining in aortas from
ApoE-deficient mice. Lederman
t al. (3) reported that the 3H-2dG signal from rabbit plaques
on autoradiography originates not only from macrophage-
rich areas, but also from smooth muscle cell (SMC) rich
areas. Mou et al. (21) showed that inflammatory cells in the
focus of microdialysis probe implantation in rats consumed
relatively small amounts of 2dG infused through the probe.
This discrepancy is not surprising, as many studies per-
formed in untransformed and cancer cell lines (17,22,23)
have shown that numerous factors can affect glucose uptake,
but those factors do not apply universally to all cell types.
In light of the crucial clinical importance of understand-
ing the mechanism that produces the FdG signal in asso-
ciation with atherosclerotic plaques, and the meaning of
changes in this signal, this study used cells that participate in
atherogenesis and well-characterized pro-atherogenic con-
ditions in vitro to explore potential mechanisms of increased
FdG uptake in atherosclerotic plaques. In particular, this
study tested the hypothesis that inflammatory activation of
macrophages and other cells found in atheromata increases
glucose uptake in response to pro-inflammatory mediators
implicated in atherogenesis. Our results show that SMCs,
but not macrophages, increased glucose uptake when ex-
Abbreviations
and Acronyms
acLDL  acetylated low-
density lipoprotein
EC  endothelial cell
FdG  18fluorine-labeled
2-deoxy-D-glucose
GLUT  glucose
transporter
HIF  hypoxia-inducible
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LDL  low-density
lipoprotein
mRNA  messenger
ribonucleic acid
PET  positron emission
tomography
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RT-qPCR  reverse
transcription–quantitative
polymerase chain reaction
siRNA  small interfering
ribonucleic acid
SMC  smooth muscle cell
TNF  tumor necrosis
factor
2dG  2-deoxy-D-glucoseposed to pro-inflammatory cytokines. In contrast, macro-phages, foam cells, and macrophage-rich fresh specimens of
human atheromata exposed to hypoxia responded with a
greatly increased rate of glucose uptake. Although these in
vitro and ex vivo experiments may not exactly replicate the
pathophysiological conditions prevailing in atheroma, they
provide a biologic basis for understanding plaque FdG
uptake.
Methods
Reagents. Human recombinant cytokines, tested by the
manufacturer for the absence of endotoxin, were obtained
from Peprotech (Rocky Hill, New Jersey). Cytochalasin B,
2dG, and statins were purchased from Sigma (St. Louis,
Missouri), and 3H-2dG from PerkinElmer (Waltham,
Massachusetts). Simvastatin was activated by alkaline hy-
drolysis before use, according to the manufacturer’s
instructions.
Cell culture. Human peripheral blood monocytes were
isolated from freshly prepared leukocyte concentrates from
healthy donors and differentiated to macrophages, as de-
scribed (24). To test the effect of cytokines, macrophages
were incubated in RPMI 1640 containing 1% human serum
for 18 h, followed by the addition of the indicated cytokines
at final concentrations of 10 ng/ml for various periods
(25–27). Macrophage conversion into foam cells was
achieved by loading them with 50 g/ml of acetylated
low-density lipoprotein (acLDL [Biomedical Technologies,
Stoughton, Massachusetts]) for the indicated periods.
Human aortic SMCs were isolated by explant outgrowth
(28) from aortas of several 35- to 45-year-old organ donors
with no overt signs of atherosclerosis. Human venous SMCs
were isolated by explant outgrowth from saphenous veins
obtained for cardiac bypass surgery. Cells were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal
calf serum and used between passages 3 and 6. When cells
reached 90% confluence, they were incubated with Dulbecco’s
modified Eagle’s medium containing 2% fetal calf serum for
48 h, followed by the addition of the indicated cytokines as
described in preceding text.
Human vascular endothelial cells (EC) were harvested
enzymatically from saphenous veins and cultured on gelatin-
coated dishes in Dulbecco’s modified Eagle’s medium con-
taining bovine hypothalamus extract, endothelial growth
factor, and 10% fetal calf serum (29).
For culture in a hypoxic environment, cells were trans-
ferred to Modular Incubation Chambers MIC-101
(Billups-Rothenberg, Del Mar, California), which were
filled with a gas mixture containing 2% O2 (calculated PO2 
14.3 mm Hg), 5% CO2, and 93% N2, and returned to a
standard tissue culture incubator for the duration of the
experiment. Cell viability under all the experimental condi-
tions examined was 95%, as assessed by trypan blue
exclusion.
Glucose uptake assay. Glucose uptake studies were per-
formed as previously described (30,31), with some modifi-
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August 2, 2011:603–14 Glucose Uptake in Atheroma-Associated Cellscations. Cells were washed with Krebs-Ringer-Hepes buffer
(136 mM NaCl, 4.7 mM KCl, 1.25 mM MgSO4, 1.25 mM
aCl2, 50 mM HEPES) and incubated in it for 30 min at
37°C to deplete endogenous glucose stores. The 3H-2dG
and unlabeled 2dG were added to the cells (final concen-
tration, 100 M for each; specific activity of 0.5 Ci per
ample for 3H-2dG) with or without 10 M cytochalasin B
to determine nonspecific uptake. As glucose uptake at 20°C
is linear for 5 to 10 min (32), cells were incubated for 5 min
at room temperature, after which the incubation buffer was
removed, and the cells were washed twice with 25 mM
ice-cold unlabeled D-glucose to stop uptake of radiolabeled
glucose. Cells were lysed with 1% Triton X-100 (Sigma).
Lysates were used for liquid scintillation counting (Beck-
man LS 6000IC counter) and protein measurements using
bicinchoninic acid assay (Pierce, Rockford, Illinois). The
net uptake of 3H-2dG by cells is expressed as nmol of
lucose per mg of protein per minute.
Each sample was analyzed in duplicate, and the values
ere averaged. The data presented in the figures represent
ean SEM of data obtained on cells from several subjects
n for each experiment is indicated in each respective figure
egend). For glucose uptake in human carotid atheroscle-
otic lesions, fresh tissue samples were chopped in slices of
pproximately 1 mm2, placed in RPMI containing 5%
uman serum, and alternate sections were subjected to
ormoxia or hypoxia for 24 h. Glucose uptake was deter-
ined as described in preceding text, with some modifica-
ions: incubation with 3H-2dG was carried out at 37°C for
0 min, and samples were washed 5 times with phosphate-
uffered saline before liquid scintillation counting.
rotein extraction and Western blotting. Cells were lysed
ith RIPA buffer (Boston BioProducts, Worcester, Massa-
husetts) containing complete Mini Protease Inhibitor
ocktail (Roche, Indianapolis, Indiana) for 30 min on ice
ith gentle rocking. Lysates were centrifuged at 10,000g for
0 min, and equal amounts of protein from the supernatants
3 to 5 g, depending on cell type) were separated on 4% to
12% gradient Bis-Tris polyacrylamide gels (Invitrogen,
Carlsbad, California). After blotting to PVDF membranes
(Amersham, Piscataway, New Jersey) and blocking with 5%
dry milk in PBS-0.05% Tween-20 (Sigma), the blots were
probed with rabbit antibodies to glucose transporter
(GLUT) 1 (Abcam, Cambridge, Massachusetts), hexoki-
nase (HK)-1, HK-2, and -actin (Cell Signaling Technol-
ogy, Danvers, Massachusetts). Membranes were incubated
with peroxidase-coupled goat anti-rabbit IgG (Invitrogen)
and developed with a chemiluminiscence reagent (Amersham).
Ribonucleic acid isolation and reverse transcription–
quantitative polymerase chain reaction. Total ribonucleic
acid (RNA) was isolated using an RNeasy kit (Qiagen,
Valencia, California) and reverse-transcribed by Superscript II
(Invitrogen). Quantitative polymerase chain reaction (qPCR)
was performed in a MyiQ single-color real-time PCR system
using SYBR Green I (Bio-Rad). The messenger ribonucleic
acid (mRNA) levels of the various genes tested were normal-ized to 18S or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as internal controls. The primer sequences were as
follows: GAPDH, 5=-TGGGTGTGAACCATGAGAAG-3=
and 5=-GCTAAGCAGTTGGTGGTGC-3=; 18S, 5=-
ATGGCCGTTCTTAGTTGGTG-3= and 5=-GAACGC-
CACTTGTCCCTCTA-3=; human leukocyte antigen (HLA)
class II histocompatibility antigen, DR alpha chain (HLA-DR),
5=-TCTTCATCATCAAGGGATTGC-3= and 5=-
TTCTCTCTAAGAAACACCATCACCT-3=; 10 kDa
IFN-–induced protein (IP-10), 5=-GAGCCTC-
GCAGAGGAACC-3= and 5=-GAGTCAGAAA-
ATAAGGCAGC-3=; vascular cell adhesion molecule-1,
=-AAGATGGTCGTGATCCTTGG-3= and 5=-GGTG-
TGCAAGTCAATGAGA-3=; matrix metalloproteinase-1,
=-TCTGGGGTGTGGTGTCTCA-3 and 5 =-
CCTCCCATCATTCTTCAGGTT-3=; FMS-related
yrosine kinase-1, 5=-ACCCAGATGAAGTTCCTTT-
GA-3= and 5=-CCCAGTTTAAGTCTCTCCCGG-3=;
nd adipophilin, 5=-TCAGCTCCATTCTACTGTTC-
CC-3= and 5=-CCTGAATTTTCTGATTGGCACT-3=.
NA interference. Macrophages were transfected with a
ool of HK-2–specific small interfering RNA (siRNA)
uplexes (Dharmacon, Lafayette, Colorado) at 50 nM using
ipofectamine 2000 (Invitrogen), following the manufac-
urer’s instructions. A pool of nontargeting siRNA duplexes
as used as a control. Experiments were conducted 48 h
fter transfection.
mmunohistochemical study. Immunohistochemical ex-
mination used 6-m-thick frozen sections of human ca-
rotid arteries obtained from endarterectomies or autopsies
and mouse antibodies to CD68 (clone KP1, Dako, Carpin-
teria, California), -actin (clone HHF35, Enzo Life Sci-
ences, Farmingdale, New York), CD31 (Dako) or rabbit
antibodies to GLUT1 and GLUT3 (Abcam), and HK-1
and HK-2 (Cell Signaling Technology). Development was
performed with LSAB2 System-HRP (Dako Cytomation).
Micrographs of stained sections were taken with an Olym-
pus Q-color 3 digital camera attached to an Olympus BX50
microscope. For colocalization of hypoxia-inducible factor 1
(HIF-1) with HK-2, we used serial paraffin section from
human coronary arteries (n 5). Paraffin was removed with
ylene and ethanol, and sections were treated with Target
etrieval Solution (Dako) by the microwave method, as
escribed previously (33,34). After cooling for 20 min, the
ections were washed in phosphate-buffered saline and
ncubated with 0.3% hydrogen peroxide to block endoge-
ous peroxidase activity. The sections were incubated over-
ight at 4°C with mouse monoclonal anti-human HIF-1
(1:500 [BD Biosciences, San Diego, California]) or rabbit
polyclonal anti-rat HK-2 (1:500 [Chemicon International,
Temecula, California]), followed by treatment with Univer-
sal Dako LSAB kit (peroxidase, Dako). Nuclear HIF-1
staining was visualized with DAB (brown nuclei), and
sections were counterstained with methyl green (ready-to-
use, Dako). The HK-2 staining was visualized with
3-amino-9-ethyl carbazole (ready-to-use, Dako), and sec-
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(Sigma).
Statistical analysis. Statistical analysis was performed with
raphPad Prism 4.0 (GraphPad Software, La Jolla, Cali-
ornia) and StatView 5.0.1 (SAS Institute, Cary, North
arolina) software packages. Values on all graphs are
xpressed as mean  SEM of several experiments (n for
ach graph is indicated in each respective figure legend). For
nalysis of serial data (e.g., glucose uptake after different
timulations over time), areas under the curve were com-
ared with the Wilcoxon signed-rank test (35). All p values
0.05 were considered statistically significant.
esults
ro-atherogenic inflammatory stimuli do not increase
he rate of glucose uptake in human macrophages or
acrophage foam cells. Several studies have suggested
hat activated macrophages constitute the primary source of
dG signal from plaques. Therefore, we first tested whether
ro-inflammatory stimulation of primary human monocyte-
erived macrophages increases the rate of glucose uptake in
hese cells. Neither IFN- nor a mixture of cytokines found
in human atheromata (tumor necrosis factor [TNF]- 
FN-  interleukin-1) modified the rate of glucose
uptake by human macrophages at either early (minutes and
hours, data not shown) or late (days) time points (Fig. 1A).
The rate of glucose uptake remained relatively stable over
the course of the experiment and did not differ from that
observed in unstimulated cells. The reverse transcription
(RT)-qPCR performed to assess cell viability and activation
revealed an increased and sustained expression of HLA-DR
mRNA (Fig. 1B) and a transiently augmented expression of
IP-10 (CXCL10) mRNA (Fig. 1C) after IFN- stimula-
tion. Increased expression of these markers indicates that
the cells remained viable over the course of the experiment
and indeed responded to the applied stimuli.
Foam cells obtained by loading macrophages with oxi-
dized LDL exhibited rates of glucose uptake that were
similar to those in macrophages and remained unchanged
upon stimulation with IFN- or with the cytokine mix (not
hown). These data indicate that in vitro, neither human
acrophages nor macrophage-derived foam cells increase
heir rate of glucose uptake when exposed to disease-
elevant pro-atherogenic stimuli.
ypoxia increases glucose uptake in macrophages and
oam cells in culture and in human carotid endarterec-
omy specimens ex vivo. Abundant data indicate that
ypoxic conditions prevail in macrophage-rich regions of
dvanced atherosclerotic plaques (36,37). Hypoxia induces
lucose uptake in tumors in vivo and ex vivo and in tumor cells
n vitro (38–42). Seeking noninflammatory stimuli relevant to
therosclerosis that might explain increased glucose uptake in
acrophages, we further tested the hypothesis that hypoxia
egulates this process. Exposure of human macrophages to
evels of hypoxia similar to those prevailing in atherosclerotic blaques (43,44) markedly increased glucose uptake (Figs. 2A
and 2B). Addition of IFN- or cytokine mix to hypoxia did
ot further increase glucose uptake by macrophages compared
o hypoxia alone (data not shown). To characterize the re-
ponse to hypoxia under our experimental conditions, we
xamined the expression of hypoxia markers (45) by RT-
PCR. Hypoxia induced a sustained expression of matrix
etalloproteinase-1 (Fig. 2C) and transient expression of
MS-related tyrosine kinase-1 (Fig. 2D), indicating cell via-
Figure 1
Glucose Uptake and Expression of
Inflammatory Markers in Human Primary Macrophages
Exposed to Pro-Atherogenic Inflammatory Cytokines
(A) Absolute rates of glucose uptake in macrophages (MF) (n  3 to 7
donors). Prot.  protein. MF expression of (B) human leukocyte antigen (HLA)–
detergent-resistant (DR) messenger ribonucleic acid (mRNA) and (C) IP-10 RNA
(both n  3 donors and normalized to glyceraldehyde-3-phosphate dehydroge-
nase [GAPDH] RNA). All values are presented as mean  SEM. Numbers indi-
cate hours after the onset of stimulation. Circles indicate controls; squares
indicate interferon (IFN)-; and crosses indicate tumor necrosis factor (TNF)-
plus interleukin (IL)-1 plus IFN-.ility and responsiveness over the course of the experiment.
c
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August 2, 2011:603–14 Glucose Uptake in Atheroma-Associated CellsWe also tested the effect of hypoxia on macrophage-
derived foam cells. We loaded macrophages with acetylated
LDL for 3 days, then determined glucose uptake after
maintaining the cells in normoxic conditions or subjecting
them to hypoxia for 1 to 3 days. Foam cells exhibited rates
of glucose uptake that resembled those in macrophages and
that rose robustly in response to hypoxia (Fig. 2E). We
monitored the macrophage-to-foam-cell transition by ex-
amining the expression of adipophilin, a foam cell marker
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Figure 2 Glucose Uptake in Human Primary Macrophages and
(A) Absolute rates of glucose uptake in macrophages (MF) exposed to hypoxia (n
curves (AUCs) shown in (A). All values are presented as mean  SEM. *p  0.05
(RNA) and (D) of FMS-related tyrosine kinase-1 RNA (both n  3 donors and norm
oxia (n  3 to 4 donors). (F) Macrophage expression of adipophilin RNA (n  2 d
the onset of hypoxia. In F, the time axis indicates hours after the addition of acet(46,47). The RT-qPCR demonstrated that the addition of sacetylated LDL to macrophages induced a sustained expres-
sion of adipophilin mRNA (Fig. 2F).
We also examined the effect of hypoxia on glucose uptake in
fresh, macrophage-rich human carotid endarterectomy speci-
mens. Similar to its effect on isolated macrophages and foam
cells, hypoxia augmented glucose uptake in these specimens
(Figs. 3A and 3B). The relative macrophage and SMC
ontents of the atheroma samples used in these experiments
ere 20.7 5.6% and 3.8 3.7%, respectively, as assessed by
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Glucose Uptake in Atheroma-Associated Cells August 2, 2011:603–14Effect of hypoxia on the expression of proteins related to
glucose uptake in human macrophages. To explore the
underlying mechanism for hypoxia-induced glucose uptake,
we examined the effect of hypoxia on the levels of proteins
involved in glucose utilization in macrophages. Western
blotting on protein extracts from macrophages cultured in
hypoxia for up to 96 h showed strong induction of HK-2
protein, compared with normoxic cells (Fig. 4A). At the
same time, expression of GLUT-1, a glucose transporter
abundantly expressed in human macrophages, and HK-1
protein did not change after hypoxic challenge (Fig. 4A).
Immunoblot using 2 different anti-GLUT3 antibodies
could not detect the expression of this protein consistently
in macrophage extracts.
We next used siRNA-mediated knockdown to investi-
gate whether the induction of HK-2 accounts for the
increase of glucose uptake elicited by hypoxia in human
macrophages. Transfection of HK-2–specific siRNA effi-
ciently reduced the levels of HK-2 protein under normoxic
or hypoxic conditions, as compared with the transfection of
control siRNA (Fig. 4C, lanes 3 and 4 vs. lanes 1 and 2), but
did not abrogate hypoxia-induced glucose uptake (Fig. 4B),
indicating that HK-2 induction is not essential to this
process.
Statins inhibit hypoxia-induced glucose uptake in
macrophages. A randomized trial has shown that statins
reduce FdG uptake in human atherosclerotic plaques, in a
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Figure 3 Glucose Uptake in Specimens From
Human Carotid Atherosclerotic Lesions
(A) Absolute rates of glucose uptake in carotid endarterectomy specimens
from 5 donors, alternately exposed to hypoxia (blue bars) or kept in normoxia
(red bars) for 24 h. (B) Average of the glucose uptake determinations in (A).
*p  0.005. Prot.  protein.process proposed to involve attenuation of plaque inflam-mation (19). As macrophages increased glucose uptake
when exposed to hypoxia but not to pro-inflammatory
cytokines, we tested the hypothesis that statins would affect
glucose uptake in macrophages independently of their
systemic anti-inflammatory effects. Treatment of human
macrophages with various statins mitigated both basal and
hypoxia-induced glucose uptake, indicating a direct effect of
statins under these conditions (Fig. 5).
Proteins involved in glucose uptake localize in macrophage-
rich and potentially hypoxic areas of atherosclerotic lesions.
Knowing that hypoxia exists in the atherosclerotic vessel
wall (37) and that it profoundly affects glucose uptake in
human macrophages, we investigated the expression pattern
of proteins related to glucose utilization in human athero-
sclerotic plaques. We performed immunohistochemical
analysis of GLUT-1 and -3, as well as of HK-1 and -2, on
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Figure 4
Expression of Proteins Related
to Glucose Utilization in Human
Primary Macrophages Exposed to Hypoxia
(A) Representative Western blots for the expression of glucose transporter
(GLUT)-1, hexokinase (HK)-1, and HK-2 in human macrophages left in normoxia
or exposed to hypoxia. The -actin served as loading control. Numbers indicate
hours after the onset of hypoxia. (B, C) Cells were transfected with HK-2–
specific or control small interfering ribonucleic acid (siRNA) as indicated. At
24 h after transfection, cells were left in normoxia or exposed to hypoxia for
30 h, followed by glucose uptake determination (B). Knockdown efficacy was
monitored by HK-2 immunoblot, using -actin as loading control (C). Hyp  hyp-
oxia; Norm  normoxia; N.S.  not significant.
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August 2, 2011:603–14 Glucose Uptake in Atheroma-Associated Cellsfrozen sections from 3 fibrous and 3 atheromatous carotid
artery plaques, as well as nonatherosclerotic carotid artery
and aorta specimens (Fig. 6). To examine the localization of
these proteins, we immunostained adjacent sections for
macrophages (CD68) and SMCs (SM -actin). Both fi-
rous and atheromatous plaques showed abundant expres-
ion of GLUT-1, GLUT-3, HK-1, and HK-2 in
acrophage-rich regions. The SMC-rich regions of the
laques expressed predominantly GLUT-1 protein, which
lso appeared in the media of normal arteries. Normal
rteries did not express detectable levels of GLUT-3, HK-1,
r HK-2 protein.
The HK-2 colocalized with the hypoxia marker HIF-1
in macrophage-rich areas of atherosclerotic lesions, as
shown by immunohistochemical study of adjacent paraffin
sections from human atheromata (n  7) (Figs. 7A and 7C). A
egative control obtained by omission of primary anti-
odies showed negligible staining (Fig. 7D) in these
ections.
ro-atherogenic inflammatory stimuli increase the rate
f glucose uptake in human vascular SMC and EC. The
MCs constitute a predominant cell type in the intima, and
ncounter macrophage- and T-cell–derived cytokines in
any atherosclerotic lesions. Our observed abundant ex-
ression of GLUT1 in SMCs (Fig. 6) led us to test whether
MCs show altered glucose uptake when exposed to pro-
nflammatory cytokines. Human aortic SMCs stimulated
ith the cytokine mix increased their rate of glucose uptake
Figs. 8A and 8B). In particular, cytokine mix stimulation
ver 4 days resulted in a fourfold increase compared to
ehicle-treated cells. Similar results occurred in human
enous SMCs (data not shown). Interleukin-1 alone also
tended to increase glucose uptake, but to a much smaller
Control Meva Prava Simva
*
* *
#
#
#
   
G
lu
co
se
 u
pt
ak
e
  n
m
ol
/m
in
.m
g 
pr
ot
.
0
0.2
0.4
0.6
0.8
1.0
1.2
Normoxia
Hypoxia
Figure 5 Glucose Uptake in Human Primary Macrophages
Exposed to Hypoxia for 24 h in Presence of Statins
Statins (n  3 or 4 donors) were added at the onset of hypoxia at a final con-
centration of 5 M. *p  0.01 compared with normoxic control. #p  0.01
compared with hypoxic control. Red bars indicate normoxia; blue bars indicate
hypoxia. Meva  mevastatin; Prava  pravastatin; Prot.  protein; Simva 
simvastatin.and statistically insignificant extent (data not shown). Otherpro-inflammatory stimuli applied individually (TNF-,
FN-, lipopolysaccharide, granulocyte colony-stimulating
factor, granulocyte macrophage colony-stimulating factor,
or macrophage inflammatory protein-1) did not apprecia-
bly increase glucose uptake in aortic SMCs, as compared
with vehicle-treated cells. Exposure of SMCs to the cyto-
kine mix evoked a sustained induction of HLA-DR and a
transient induction of vascular cell adhesion molecule-1,
indicating that the cells remained viable and responsive over
the course of the experiment (Figs. 8C and 8D). Exposure
of arterial SMCs to hypoxia did not significantly increase
glucose uptake compared to normoxic cells (data not
shown).
Examination of the expression levels of proteins related
to glucose metabolism by immunoblot revealed that
SMCs exposed to the cytokine mix exhibited strong
induction of HK-2 compared with unstimulated cells
over a 4-day course of stimulation (Fig. 8E). Expression
of GLUT-1 and HK-1 proteins did not change after such
stimulation (Fig. 8E).
Human vascular ECs exposed to cytokine mix also
responded with an augmented rate of glucose uptake
(Figs. 8F and 8G), but no increase occurred in response to
lipopolysaccharide or TNF- exposure (data not shown).
Discussion
This study used cell types prominent in atheromata to probe
the mechanism for the increased FdG signal observed in
animal and human FdG-PET imaging studies of athero-
sclerosis. To investigate glucose uptake, we used 3H-2dG,
an FdG analogue previously shown to exhibit kinetics
similar to FdG (48,49).
Previous studies of glucose uptake by activated mononu-
clear cells in vitro (16–18,50) suggested that certain stimuli
may increase glucose uptake by these cells. Those studies,
performed on cells from different sources, often employed
relatively short-term treatments, which may not replicate
chronic exposure of cells to inflammatory stimuli present in
plaques. In addition, some studies used stimulators of
unknown relevance to atherosclerosis, such as phorbol
esters. Our study, which examined human macrophages
exposed to potent pro-atherogenic stimuli for extended
periods of time, demonstrated that mere inflammatory
activation did not alter the rate of glucose uptake in these
cells.
Previous studies have speculated, but have not directly
demonstrated, that inflammatory activation of macrophages
in plaques may boost glucose uptake by these cells and result
in higher FdG signals. This assumption derived from earlier
studies showing positive correlations between the intensity
of FdG signals in plaques in vivo and staining for macro-
phage markers ex vivo (2,5,14,15). Additionally, the obser-
vation that treatment of atherosclerotic patients with statins—
drugs that can exert anti-inflammatory effects—decreases
610 Folco et al. JACC Vol. 58, No. 6, 2011
Glucose Uptake in Atheroma-Associated Cells August 2, 2011:603–14FdG uptake (19), has reinforced the notion of a direct
correlation between plaque inflammation and glucose up-
take. Our data establish hypoxia as a potent and sufficient
stimulus for increased glucose uptake in macrophages and
foam cells, and therefore suggest an alternative scenario
whereby hypoxia, rather than pro-inflammatory stimula-
tion, could augment FdG uptake in human plaques. In this
context, our surprising finding that statins inhibit both basal
and hypoxia-induced glucose uptake in macrophages sug-
Figure 6 Representative Immunohistochemical Stainings
Representative immunohistochemical stainings of human atherosclerotic carotid le
(HK)-1, HK-2, CD68 (macrophages), and -actin (smooth muscle cell [SMC]) protei
tous plaque; and (right panel) staining of a nonatherosclerotic human carotid artegests that statin-induced decreases in FdG signals in humanatheroma may reflect a blunted response to hypoxia rather
than an anti-inflammatory action of these drugs.
Experiments that explored the underlying mechanism for
hypoxia-induced glucose uptake revealed that hypoxia in-
duces HK-2 expression in human macrophages. However,
siRNA-mediated knockdown under conditions that re-
duced HK-2 protein expression in hypoxia to levels similar
to those detected in normoxic, nonstimulated cells (Fig. 4C,
lanes 1 vs. 4), did not suppress hypoxia-induced glucose
and normal arteries for glucose transporter (GLUT)-1, GLUT-3, hexokinase
ft panel) staining of a fibrous plaque; (middle panel) staining of an atheroma-
UT-1, GLUT-3, and HK-2) or aorta (HK-1, CD68, and -actin).sions
ns: (le
ry (GLuptake. This result suggests that glucose phosphorylation is
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August 2, 2011:603–14 Glucose Uptake in Atheroma-Associated Cellsnot the limiting step in the process of glucose uptake, but
may become limiting for glucose metabolism under condi-
tions of increased influx, such as hypoxia. Our data indicate
that the protein levels of GLUT1, a glucose transporter
abundantly expressed in macrophage-rich regions of ather-
oma (Fig. 6), remain unchanged upon hypoxic stimulation.
Experiments that explored whether hypoxia affects the
shuttling of GLUT1 between plasma membrane and intra-
cellular compartments or its targeting to detergent-insoluble
membrane domains (51–53) did not show changes in
GLUT1 subcellular localization (data not shown). Thus,
fuller understanding of the mechanisms by which hypoxia
increases glucose uptake in human macrophages will require
further investigation that includes examination of GLUT
activity, which may not correlate with GLUT protein
expression.
Prior imaging studies did not detect any association
between FdG uptake and staining for SMCs, another
abundant cell type in atherosclerotic plaques (5,15). Con-
versely, some earlier studies that used cells from different
species have shown an increase in SMC glucose uptake in
response to different activating stimuli (54,55). Our study
demonstrates that human arterial SMCs exposed to a
mixture of IFN-, interleukin-1, and TNF-, well-known
regulators of SMC functions in atherosclerosis (56–58),
exhibit a sustained increase in glucose uptake. The SMC
numbers may exceed those of macrophages in some athero-
sclerotic plaques (59–62), suggesting that SMCs can con-
tribute to the FdG signal. In support of this view, Lederman
Figure 7 Colocalization of HIF-1 and HK-2 in Macrophage-Rich
(A, B) Staining with rabbit-anti hexokinase (HK)-2 antibody, at high and low magni
serial sections. (D) Negative control obtained by omission of primary antibodies. A
The box in (B) indicates the area amplified in (A).et al. (3) showed the highest 3H-2dG accumulation inSMC-positive and macrophage-positive subintimal regions
in balloon-injured iliac arteries from atherosclerotic rabbits.
Our data also corroborate previous findings that vascular
ECs stimulated with pro-atherogenic stimuli exhibit in-
creased rates of glucose uptake and may contribute to the
FdG signal (17,63,64). As the amount of ECs in plaques
increases due to neovascularization (65), these cells may also
contribute to the overall FdG-PET signal from plaques in
vivo.
The in vitro approach used in this study serves to
dissect the contribution of different cellular elements and
biological factors to glucose uptake in plaques, but has
the important limitation that in vitro conditions do not
replicate all of the complexity of cellular interactions in
atherosclerotic plaques. In this regard, our results using
human carotid atheroma specimens in organoid culture
support the in vitro data and demonstrate that hypoxia
can increase glucose uptake in the complex multicellular
context of atheromata.
Conclusions
Collectively, our data show that different mechanisms for
stimulation of macrophages, SMCs, and ECs may con-
tribute importantly to increasing glucose uptake and,
hence, to FdG signal in atherosclerotic plaques. Macro-
phages or foam cells, abundant constituents of inflamed
atheromata, when cultivated in isolated culture do not
seem to increase glucose uptake in response to inflam-
ions of Human Atheroma
, respectively. (C) Nuclear hypoxia-inducible factor (HIF)-1 staining in
k indicates the arterial lumen. Original magnification is indicated on each panel.Reg
fication
sterismatory stimulation, although vascular SMCs and ECs do
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Glucose Uptake in Atheroma-Associated Cells August 2, 2011:603–14so. These results suggest that intraplaque hypoxia may
contribute to the intensity of FdG accumulation in
atheromata. Interpretation of clinical trials that use FdG
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Figure 8 Glucose Uptake in Human Primary Vascular SMCs and
(A) Absolute rates of glucose uptake (circles indicate control; squares indicate
(B) comparison of areas under the curves (AUCs) from (A) in human primary a
human leukocyte (HLA)–detergent-resistant (DR) ribonucleic acid (RNA), and (D
normalized to glyceraldehyde-3-phosphate dehydrogenase [GAPDH] and 18S RN
and -actin in human aortic SMCs exposed to inflammatory stimuli. C  contro
uptake, and (G) comparison of AUCs from (F) in human primary vascular endo
0.05.signals to monitor responses to interventions should takethese findings into account. Studies testing this hypoth-
esis in animals and in clinical settings will help us probe
this important issue and understand more fully the source
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